Literature DB >> 21216938

Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells.

Seema Gupta1, Tulay Koru-Sengul, Susanne M Arnold, Gayathri R Devi, Mohammed Mohiuddin, Mansoor M Ahmed.   

Abstract

In this study, the role of hyper-radiation sensitivity (HRS) in potentiating the effects of cisplatin by low-dose fractionated radiation (LDFRT) was evaluated in four human non-small cell lung cancer cell lines. Presence of HRS and cisplatin enhancement ratio (CER) by LDFRT/2 Gy was assessed using colony-forming and apoptotic assays. Cell-cycle disturbances were studied by flow cytometry. Expression of genes involved in apoptosis was assessed using real-time reverse transcriptase PCR arrays. H-157 cells showed a distinct HRS region, followed by UKY-29 and A549 cells, whereas it was absent in H460 cells, which when lack HRS showed maximum CER with LDFRT (4 × 0.5 Gy) both by clonogenic inhibition and by apoptosis compared with single fraction of 2 Gy whereas the most radioresistant A549 cells had the least CER, with no significant differences between LDFRT or 2 Gy. Interestingly, in H-157 cells, a more pronounced CER was observed with LDFRT when assessed by apoptosis but clonogenic inhibition-CER was higher with 2 Gy than with LDFRT. Excluding H-157 cells, the CER by LDFRT was inversely proportional to radioresistance [(determined by D(0), the dose to reduce survival by 67% from any point on the linear portion of the survival curve or surviving fraction (SF) at 2 Gy (SF(2))] of the cells. LDFRT alone or in combination with cisplatin induced larger number of proapoptotic genes than 2 Gy or cisplatin + 2 Gy in cells showing HRS when compared to H460 cells that lack HRS. These findings indicate that chemopotentiation by LDFRT is correlated more with the intrinsic radiation sensitivity of the non-small lung cancer cells than the HRS phenomenon whereas the mode of cell killing is both through apoptosis and clonogenic inhibition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21216938     DOI: 10.1158/1535-7163.MCT-10-0630

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  21 in total

Review 1.  Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy.

Authors:  Anish Prasanna; Mansoor M Ahmed; Mohammed Mohiuddin; C Norman Coleman
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  A Logarithmic Formula to Describe the Relationship between the Increased Radiosensitivity at Low Doses and the Survival at 2 Gray.

Authors:  Faika A Azooz; Suzan K Hashim
Journal:  Sultan Qaboos Univ Med J       Date:  2013-11-08

3.  p16INK4a Status and Response to Induction Low-Dose Fractionated Radiation in Advanced Head and Neck Cancer.

Authors:  Natalie L Silver; Susanne M Arnold; John F Gleason; Mahesh Kudrimoti; Yolanda Brill; Emily V Dressler; Joseph Valentino
Journal:  Ann Otol Rhinol Laryngol       Date:  2015-03-25       Impact factor: 1.547

4.  CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance.

Authors:  Rui Liu; Ming Fan; Demet Candas; Lili Qin; Xiaodi Zhang; Angela Eldridge; June X Zou; Tieqiao Zhang; Shuaib Juma; Cuihong Jin; Robert F Li; Julian Perks; Lun-Quan Sun; Andrew T M Vaughan; Chun-Xu Hai; David R Gius; Jian Jian Li
Journal:  Mol Cancer Ther       Date:  2015-07-03       Impact factor: 6.261

5.  Contribution of Dual Oxidase 2 (DUOX2) to Hyper-Radiosensitivity in Human Gastric Cancer Cells.

Authors:  Duc M Nguyen; Palak R Parekh; Elizabeth T Chang; Navesh K Sharma; France Carrier
Journal:  Radiat Res       Date:  2015-07-24       Impact factor: 2.841

6.  Synergetic Influence of Bismuth Oxide Nanoparticles, Cisplatin and Baicalein-Rich Fraction on Reactive Oxygen Species Generation and Radiosensitization Effects for Clinical Radiotherapy Beams.

Authors:  Noor Nabilah Talik Sisin; Khairunisak Abdul Razak; Safri Zainal Abidin; Nor Fazila Che Mat; Reduan Abdullah; Raizulnasuha Ab Rashid; Muhammad Afiq Khairil Anuar; Wan Nordiana Rahman
Journal:  Int J Nanomedicine       Date:  2020-10-12

7.  Protective effect of acetyl-l-carnitine against cisplatin ototoxicity: role of apoptosis-related genes and pro-inflammatory cytokines.

Authors:  Z Altun; Y Olgun; P Ercetin; S Aktas; G Kirkim; B Serbetcioglu; N Olgun; E A Guneri
Journal:  Cell Prolif       Date:  2013-11-29       Impact factor: 6.831

8.  Chromatin Modulation by Histone Deacetylase Inhibitors: Impact on Cellular Sensitivity to Ionizing Radiation.

Authors:  France Carrier
Journal:  Mol Cell Pharmacol       Date:  2013-01-01

9.  Radiosensitization Effects by Bismuth Oxide Nanoparticles in Combination with Cisplatin for High Dose Rate Brachytherapy.

Authors:  Noor Nabilah Talik Sisin; Khairunisak Abdul Razak; Safri Zainal Abidin; Nor Fazila Che Mat; Reduan Abdullah; Raizulnasuha Ab Rashid; Muhammad Afiq Khairil Anuar; Nur Hamizah Mohd Zainudin; Nashrulhaq Tagiling; Norazlina Mat Nawi; Wan Nordiana Rahman
Journal:  Int J Nanomedicine       Date:  2019-12-18

10.  Towards predicting the response of a solid tumour to chemotherapy and radiotherapy treatments: clinical insights from a computational model.

Authors:  Gibin G Powathil; Douglas J A Adamson; Mark A J Chaplain
Journal:  PLoS Comput Biol       Date:  2013-07-11       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.